SAN DIEGO and PENNINGTON, N.J., Dec.
21, 2018 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer
immunotherapies, announced today that Joon
Kim, J.D., a partner at Lee & Ko, has been appointed to
OncoSec's Board of Directors. The appointment was made in parallel
to the investment by Alpha Holdings, Inc. (kosdaq:117670) of
$15 million at $1.50 share, which was completed on December 7, 2018. The appointment was effective
December 20, 2018.
"This is an exciting time to join OncoSec as they are moving
into late-stage development of their lead programs and beginning to
see the broad potential of their pipeline," said Joon Kim, J.D., Board Member of OncoSec. "I look
forward to bringing my deep expertise in corporate law to bear as
they continue their mission."
"Joon brings more than 20 years of legal experience, including
advising corporate clients on a broad range of litigation and
transactional matters," said Daniel J.
O'Connor, President and Chief Executive Officer of OncoSec.
"His insights will be valuable to our Company as we continue to
advance the development of TAVO™ towards commercialization for the
treatment of a range of tumors."
Joon Kim is a highly accomplished
attorney and partner in Lee & Ko's Corporate, International
Litigation and Dispute Resolution, and White Collar Crime Practice
Groups. Mr. Kim advises clients, both domestic and international,
on a broad range of litigation, dispute-resolution and
transactional matters. With a particularly strong background in
representing clients in court proceedings, Mr. Kim has a
comprehensive understanding of every stage of the litigation
process, including all aspects of initial investigatory/discovery
proceedings, settlement negotiations, hearings, motions, trials,
evidentiary issues and the handling of post-judgment challenges and
appeals.
Prior to joining Lee & Ko, Mr. Kim worked for several years
as a litigation lawyer and served from 2008 to 2017 as a public
prosecutor in California. Mr. Kim
has first-chaired both jury and non-jury trials, and has been
trained in all aspects of litigation. During his time as a public
prosecutor, Mr. Kim also had the experience of serving in 2016 as a
research fellow in Korea at the Institute of Justice, under the
auspices of the Korea Ministry of Justice, where he worked together
with Korean public prosecutors. Joon received his J.D. from
Berkeley School of Law and his B.S. from the Berkeley School of
Business.
In addition, the company has appointed Julie Shin, U.S. patent attorney and a member of
Lee & Ko's Intellectual Property, Healthcare, and Life Sciences
Practice Groups as a Board Observer. Ms. Shin has extensive
experience with intellectual property matters, having advised and
assisted clients in a broad range of legal contexts, including
litigation, licensing and other transactions, due diligence,
product clearance and opinions, and IP asset management. She
received her J.D. from the University of
Virginia School of Law and her B.S. from Yale University.
About OncoSec Medical Incorporated
OncoSec is a
clinical-stage biotechnology company focused on developing
cytokine-based intratumoral immunotherapies to stimulate the body's
immune system to target and attack cancer. OncoSec's lead
immunotherapy platform – TAVO™ (tavokinogene telseplasmid) –
enables the intratumoral delivery of DNA-based interleukin-12
(IL-12), a naturally occurring protein with immune-stimulating
functions. The technology, which employs electroporation, is
designed to produce a controlled, localized expression of IL-12 in
the tumor microenvironment, enabling the immune system to target
and attack tumors throughout the body. OncoSec has built a
deep and diverse clinical pipeline utilizing TAVO™ as a potential
treatment for multiple cancer indications either as a monotherapy
or in combination with leading checkpoint inhibitors; with the
latter potentially enabling OncoSec to address a great unmet
medical need in oncology: anti-PD-1 non-responders. Results
from recently completed clinical studies of TAVO™ have demonstrated
a local immune response, and subsequently, a systemic effect as
either a monotherapy or combination treatment approach. In
addition to TAVO™, OncoSec is identifying and developing new
DNA-encoded therapeutic candidates and tumor indications for use
with its ImmunoPulse® platform. For more information, please
visit www.oncosec.com.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "can," "may," "will,"
"suggest," "look forward to," "potential," "understand," and
similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data, safety
and technical issues; our ability to raise additional funding
necessary to fund continued operations; and the other factors
discussed in OncoSec's filings with the Securities and Exchange
Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
Michael Lampe
Scient Public Relations, Inc.
(484) 575-5040
michael@scientpr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-announces-appointment-of-joon-kim-jd-to-board-of-directors-300770009.html
SOURCE OncoSec Medical Incorporated